Gilead Sciences shows positive results for remdesivir as COVID-19 drug
Category: #health  By Mateen Dalal  Date: 2020-05-01
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Gilead Sciences shows positive results for remdesivir as COVID-19 drug

Gilead Sciences, the maker of remdesivir, has recently revealed positive results from trials for the drug. The trials were conducted to evaluate the potential of the medication as a treatment for the novel coronavirus.

The trials examined the response of patients to either 5-day or 10-day treatments of remdesivir. According to Gilead, the patients undergoing the 5-day treatment showed similar improvement as those treated for twice the timeframe.

Merdad Parsey, Gilead Sciences’ chief medical officer has reportedly stated that the trial shows the potential of certain patients to be treated under the 5-day remdesivir regimen, which could considerably increase the number of patients that could be treated with the present remdesivir supply. This could prove extremely beneficial in the current pandemic setting, enabling healthcare facilities and hospitals to provide efficient treatment to patients in urgent need.

The drug is also being tested locally. For instance, St. Joseph Hospital revealed its plans to conduct some remdesivir trials earlier in the month, which marks a significant feat for the small rural facility. The hospital is conducting two clinical trials, one for moderate symptoms and one to treat more severe symptoms.

Chief executive of St. Joseph Health, Dr. Roberta Luskin-Hawk, stated that one of the patients to receive the treatment was a local patient hospitalized at the St. Joseph Hospital, exhibiting severe COVID-19 symptoms, including dropping oxygen, making them an ideal trial candidate. Dr. Luskin-Hawk also expressed her belief that the drug shows promise as a potential COVID-19 treatment. She also recounted her anticipation to gain access to the drug, in order to leverage its ability to reduce viral loads in patients, especially those suffering from the coronavirus.

The hospital has not offered further information regarding the local trials.

There are no medications currently approved for the treatment of COVID-19, a respiratory disorder that has claimed the lives of over 227,000 people across the globe.

Source Credit: https://www.times-standard.com/2020/04/29/covid-19-drug-shows-promise-in-two-clinical-trials/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

By Mateen Dalal

U.S. President Joe Biden will reportedly nominate Jonathan Kanter, a competition lawyer, and fervid Google critic, to head the antitrust division of the Justice Department. Kanter has been actively representing several companies in competition cases...